Publication: Effect of Mineralocorticoid Receptor Blockade on Hippocampal-Dependent Memory in Obese Adults
Open/View Files
Date
2015
Published Version
Journal Title
Journal ISSN
Volume Title
Publisher
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Rotenstein, Lisa S., Margaret Sheridan, Rajesh Garg, and Gail K. Adler. 2015. “Effect of Mineralocorticoid Receptor Blockade on Hippocampal-Dependent Memory in Obese Adults.” Obesity (Silver Spring, Md.) 23 (6): 1136-1142. doi:10.1002/oby.21104. http://dx.doi.org/10.1002/oby.21104.
Research Data
Abstract
Objective: The hippocampus is crucial for paired-associate learning. Obesity is associated with increased MR activity in peripheral and possibly central tissues, decreased hippocampal size in humans and impaired hippocampal learning in rodents. The MR is expressed in hippocampal neurons and MR blockade improves hippocampal learning in obese animals. We sought to determine whether MR blockade would modulate paired-associate learning in obese men and women. Design and Methods Men and women ages 20-61 years with BMIs between 30-45 kg/m2 were randomly assigned to placebo (n=11; 7 women) or 50 mg spironolactone daily (n=12; 7 women) for six weeks. At baseline and post treatment, subjects underwent a clinical and hormonal evaluation. They also underwent a computerized task that assesses paired-associate learning and has been shown by functional magnetic resonance imaging to activate the hippocampus. Results: In an ANCOVA model that adjusted for baseline paired-associate learning, age, and race, spironolactone treatment was associated with a significant (p=0.043) improvement in hippocampal memory as compared to placebo treatment. Conclusions: Our findings demonstrate, for the first time, that blocking MR with chronic, low-dose spironolactone treatment improves paired-associate learning in obese individuals, suggesting that MR activation contributes to hippocampal memory modulation in humans.
Description
Other Available Sources
Keywords
Obesity, Neurochemistry, Cardiovascular Drugs
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service